Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Clinuvel Pharmaceuticals ( (AU:CUV) ) has issued an announcement.
Clinuvel Pharmaceuticals Limited announced the cessation of 36,323 performance rights due to the expiry of options or other convertible securities without exercise or conversion. This development may impact the company’s capital structure and could influence investor perceptions regarding the company’s financial strategies and future growth prospects.
The most recent analyst rating on (AU:CUV) stock is a Buy with a A$13.00 price target. To see the full list of analyst forecasts on Clinuvel Pharmaceuticals stock, see the AU:CUV Stock Forecast page.
More about Clinuvel Pharmaceuticals
Clinuvel Pharmaceuticals Limited operates in the pharmaceutical industry, focusing on developing and commercializing treatments for severe skin disorders. The company is known for its innovative therapies and has a market focus on providing solutions for conditions related to skin pigmentation and photoprotection.
Average Trading Volume: 140,787
Technical Sentiment Signal: Sell
Current Market Cap: A$601.5M
For detailed information about CUV stock, go to TipRanks’ Stock Analysis page.